Press release
Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investor Alert: Deadline in Lawsuit on September 15, 2025
A Deadline is coming up on September 15, 2025 in the lawsuit for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) .
Investors who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have certain options and there are strict and short deadlines running. Deadline: September 15, 2025. Capricor Therapeutics, Inc. (NASDAQ: CAPR) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges on behalf of purchasers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) common shares between October 9, 2024 and July 10, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 9, 2024 and July 10, 2025, the defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration, and that the Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel, causing Plaintiff and other shareholders to purchase Capricor's securities at artificially inflated prices.
Those who purchased shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investor Alert: Deadline in Lawsuit on September 15, 2025 here
News-ID: 4168938 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Capricor
Dilated Cardiomyopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PM …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dilated Cardiomyopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Dilated Cardiomyopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Dilated Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Exosome Technologies Market Report- Key companies: Capricor Therapeutics Inc, Ev …
Global Exosome Technologies Market research study offers a complete analysis of critical aspects of the current market situation including market competition, segmentation, geographical progress, and dynamic factors during the forecast period. The Exosome Technologies Market report offers insights into the potential size, volume, production, growth, revenue, and other estimations for the global as well as regional markets. This report also explains the Exosome Technologies Market share by company, investment strategies,…
Exosome Therapeutic Market In-depth Analysis by Statistics & Outlook 2027 |ReNeu …
The Global Exosome Therapeutic Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Exosome Therapeutic Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Exosome Therapeutic market examines the primary segments of the market. This intelligent study provides historical data from forecast from 2021 to 2027.It also provides the details such as whether the customers…
Dilated Cardiomyopathy Market 2019 Analysis and Precise Outlook - Capricor Thera …
The report titled “Dilated Cardiomyopathy Market” has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners, and industry experts.
The global Dilated Cardiomyopathy market is valued…
2019 Global Exosome Technologies Market- Capricor, Codiak and Evox Therapeutics …
Researchmoz added Most up-to-date research on "Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players" to its huge collection of research reports.
GBI Research’s latest report, Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players, explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including…
Global Intravenous-to-Subcutaneous Drug Market 2017 : Baxter, Britannia, Caprico …
Global Intravenous-to-Subcutaneous Drug Market 2016-2017
A market study based on the " Intravenous-to-Subcutaneous Drug Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Intravenous-to-Subcutaneous Drug Market 2017’. The research report analyses the historical as well as present performance of the worldwide Intravenous-to-Subcutaneous Drug industry, and makes predictions on the future status of Intravenous-to-Subcutaneous Drug market on the basis of this analysis.
Get Free Sample Copy…
